These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 32706146)
1. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget's disease: Four cases and a review. Sekiguchi N; Kubota S; Noguchi T; Fukushima T; Kobayashi T; Kanda S; Koizumi T; Miyake T; Shirai T; Okuyama R J Dermatol; 2020 Nov; 47(11):1276-1279. PubMed ID: 32706146 [TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva. Bartoletti M; Mazzeo R; De Scordilli M; Del Fabro A; Vitale MG; Bortot L; Nicoloso MS; Corsetti S; Bonotto M; Scalone S; Giorda G; Sorio R; Andreetta C; Meacci ML; De Vivo R; Fasola G; Sopracordevole F; Puglisi F Int J Gynecol Cancer; 2020 Nov; 30(11):1672-1677. PubMed ID: 32998859 [TBL] [Abstract][Full Text] [Related]
4. Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary Paget's disease: A case report and review of the literature. Ichiyama T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Mamiya K; Koizumi T; Hama Y Mol Clin Oncol; 2017 Nov; 7(5):763-766. PubMed ID: 29181166 [TBL] [Abstract][Full Text] [Related]
5. Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy. Takahagi S; Noda H; Kamegashira A; Madokoro N; Hori I; Shindo H; Mihara S; Hide M J Dermatol; 2009 Aug; 36(8):457-61. PubMed ID: 19691751 [TBL] [Abstract][Full Text] [Related]
6. A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy. Hanawa F; Inozume T; Harada K; Kawamura T; Shibagaki N; Shimada S Case Rep Dermatol; 2011 Sep; 3(3):223-7. PubMed ID: 22135629 [TBL] [Abstract][Full Text] [Related]
7. Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein. Ogawa T; Nagashima Y; Wada H; Akimoto K; Chiba Y; Nagatani T; Inayama Y; Yao M; Aoki I; Ikezawa Z Hum Pathol; 2005 Dec; 36(12):1273-80. PubMed ID: 16311120 [TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget's disease (EMPD-HER2DOC). Hirai I; Tanese K; Nakamura Y; Fukuda K; Ouchi T; Hayashida T; Kameyama K; Abe T; Amagai M; Funakoshi T Oncologist; 2024 Sep; 29(9):e1201-e1208. PubMed ID: 38823035 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptors are frequently expressed in mammary and extramammary Paget's disease. Liegl B; Horn LC; Moinfar F Mod Pathol; 2005 Oct; 18(10):1283-8. PubMed ID: 15920545 [TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06. Sohn BS; Kim J; Kim M; Hong JY; Lee J; Park SE; Kim H; Lee HJ; Kang EJ; Lee SI; Lee IH; Huh SJ; Jo J; Kim HY Cancer Med; 2023 Jul; 12(14):15159-15175. PubMed ID: 37264748 [TBL] [Abstract][Full Text] [Related]
12. Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease. Hirai I; Tanese K; Nakamura Y; Otsuka A; Fujisawa Y; Yamamoto Y; Hata H; Fujimura T; Matsushita S; Yoshino K; Kameyama K; Amagai M; Funakoshi T Med Oncol; 2018 May; 35(6):92. PubMed ID: 29744813 [TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease. Lu X; Zhang P; Zhu Y; Ye D Oncol Lett; 2019 Mar; 17(3):2677-2686. PubMed ID: 30854041 [TBL] [Abstract][Full Text] [Related]